MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
- Patent covers compositions of clofazimine, and methods for treating lung infections
- Development of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial (NTM) lung disease
“We believe this patent represents important protection for our lead pipeline asset, MNKD-101, that could potentially improve therapy for a disease that is increasingly on the rise globally,” said
Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence worldwide. It is a serious infection that is caused by bacteria common in the environment that can lead to a reduction in lung function, cough, fatigue, and quality of life. It is estimated that approximately 86,000-180,000 people in the
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
This press release contains forward-looking statements about the implications of clinical data and the potential safety of an investigational product that involve risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intends”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of an investigational drug product may not yield successful results or results that are consistent with earlier testing, and other risks detailed in MannKind’s filings with the
MNKD-101 is an investigational product that is not approved for any use in any country.
MannKind: Christie Iacangelo, Corporate Communications (818) 292-3500 Email: email@example.com Rose Alinaya, Investor Relations (818) 661-5000 Email: firstname.lastname@example.org